A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

AT-101, prednisone and docetaxel

docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3

DRUG

placebo, prednisone and docetaxel

docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3

Trial Locations (35)

Unknown

Colorado Springs

New Port Richey

Ocoee

Fishers

Burnsville

Las Vegas

Albuquerque

Las Cruces

Raleigh

Kettering

Eugene

Spartanburg

Amarillo

Arlington

Austin

Dallas

Denton

Midland

Paris

Webster

Fairfax

Norfolk

Kennewick

Vancouver

Barnaul

Engel's

Kazan'

Kursk

Kuzmolovsky

Moscow

Saint Petersburg

Sochi

Stavropol

Voronezh

Yekaterinburg

Sponsors
All Listed Sponsors
lead

Ascenta Therapeutics

INDUSTRY

NCT00571675 - A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) | Biotech Hunter | Biotech Hunter